Thyroid Dysfunction after Atezolizumab and Bevacizumab Is Associated with Favorable Outcomes in Hepatocellular Carcinoma

Introduction: Atezolizumab and bevacizumab (Ate/Bev) combination has become the new first-line systemic therapy for unresectable hepatocellular carcinoma (HCC). Although several studies reported thyroid dysfunction after treatment with immune checkpoint inhibitors, the clinical and immunological sig...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Young Shin Song, Hannah Yang, Beodeul Kang, Jaekyung Cheon, Ilhwan Kim, Hyeyeong Kim, Won Suk Lee, Yun Beom Sang, Sanghoon Jung, Ho Yeong Lim, Vincent E. Gaillard, Chan Kim, Hong Jae Chon
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Karger Publishers 2023-05-01
coleção:	Liver Cancer
Assuntos:	hepatocellular carcinoma thyroid adverse events atezolizumab bevacizumab
Acesso em linha:	https://beta.karger.com/Article/FullText/531182
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!